Top

Published in:

01-11-2015 | Research Article

Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers

Authors: Qianshan Ding, Du He, Ke He, Qian Zhang, Meng Tang, Jinfen Dai, Hanlin Lv, Xiaochen Wang, Guoan Xiang, Honggang Yu

Published in: Tumor Biology | Issue 11/2015

Abstract

The aim of our work is to clarify the clinical implication and functional role of tripartite motif 21 (TRIM21) in hepatocellular carcinoma (HCC). We validated that TRIM21 was downregulated in liver cancer samples by immunohistochemical (IHC) staining. We also demonstrated that its downregulation was associated with several clinicopathologic features such as tumor numbers, T stage, Barcelona Clinic Liver Cancer (BCLC) stage, and Cancer of the Liver Italian Program (CLIP) stage of HCC patients. Importantly, the expression of TRIM21 in tumor samples is significantly correlated with the prognosis of the patients. We further silenced TRIM21 in HCC cell HepG2 and LM3 and confirmed that TRIM21 silencing will promote cancer cell proliferation (CCK-8 assay), colony forming (plate colony-forming assay), migration (transwell assay), and the ability of antiapoptosis (annexin V-FITC/PI staining) in vitro. Then, we predicted gene sets influenced by TRIM21 by using bioinformatic tools. For the first time, we prove that TRIM21 is a potential tumor suppressor in HCC and its low expression indicates poor prognosis. Our findings provide useful insight into the mechanism of HCC origin and progression and offer clues to novel HCC therapies.

Jemal A, Bray F, Center MM, Ferlay J, Ward E. Forman D. Global Cancer Stat. 2011;61:69–90.

Kishi Y, Shimada K, Nara S, Esaki M, Kosuge T. Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma. World J Hepatol. 2014;6:836–43.CrossRefPubMedPubMedCentral

Ikeda K, Inoue S. TRIM proteins as RING finger E3 ubiquitin ligases. Adv Exp Med Biol. 2012;770:27–37.CrossRefPubMed

Schwamborn JC, Berezikov E, Knoblich JA. The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell. 2009;136:913–25.CrossRefPubMedPubMedCentral

Uchil PD, Pawliczek T, Reynolds TD, Ding S, Hinz A, Munro JB, et al. TRIM15 is a focal adhesion protein that regulates focal adhesion disassembly. J Cell Sci. 2014;127:3928–42.CrossRefPubMedPubMedCentral

Cambiaghi V, Giuliani V, Lombardi S, Marinelli C, Toffalorio F, Pelicci PG. TRIM proteins in cancer. Adv Exp Med Biol. 2012;770:77–91.CrossRefPubMed

Kawai T, Akira S. Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins. EMBO Mol Med. 2011;3:513–27.CrossRefPubMedPubMedCentral

Petrera F, Meroni G. TRIM proteins in development. Adv Exp Med Biol. 2012;770:131–41.CrossRefPubMed

Kanno Y, Watanabe M, Kimura T, Nonomura K, Tanaka S, Hatakeyama S. TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer. Acta Histochem. 2014;116:708–12.CrossRefPubMed

10.

Bell JL, Malyukova A, Kavallaris M, Marshall GM, Cheung BB. TRIM16 inhibits neuroblastoma cell proliferation through cell cycle regulation and dynamic nuclear localization. Cell Cycle. 2013;12:889–98.CrossRefPubMedPubMedCentral

11.

Liu Y, Raheja R, Yeh N, Ciznadija D, Pedraza AM, Ozawa T, et al. TRIM3, a tumor suppressor linked to regulation of p21 (Waf1/Cip1). Oncogene. 2014;33:308–15.CrossRefPubMed

12.

Reddy BA, van der Knaap JA, Bot AG, Mohd-Sarip A, Dekkers DH, Timmermans MA, et al. Nucleotide biosynthetic enzyme GMP synthase is a TRIM21-controlled relay of p53 stabilization. Mol Cell. 2014;53:458–70.CrossRefPubMed

13.

McEwan WA, James LC. TRIM21-dependent intracellular antibody neutralization of virus infection. Prog Mol Biol Transl Sci. 2015;129:167–87.CrossRefPubMed

14.

Kyriakidis NC, Kapsogeorgou EK, Gourzi VC, Konsta OD, Baltatzis GE, Tzioufas AG. Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway. Clin Exp Immunol. 2014;178:548–60.CrossRefPubMedPubMedCentral

15.

Young JA, Sermwittayawong D, Kim HJ, Nandu S, An N, Erdjument-Bromage H, et al. Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production. J Biol Chem. 2011;286:6521–31.CrossRefPubMed

16.

Espinosa A, Zhou W, Ek M, Hedlund M, Brauner S, Popovic K, et al. The Sjogren’s syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol. 2006;176:6277–85.CrossRefPubMed

17.

Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70:10202–12.CrossRefPubMedPubMedCentral

18.

Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10:e1001453.CrossRefPubMedPubMedCentral

19.

Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013;5:186ra66.CrossRefPubMedPubMedCentral

20.

Menéndez A, Gómez J, Escanlar E, Caminal-Montero L, Mozo L. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection. Autoimmunity. 2013;46:32–9.CrossRefPubMed

21.

Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun. 2012;39:77–82.CrossRefPubMed

22.

Vaysburd M, Watkinson RE, Cooper H, Reed M, O’Connell K, Smith J, et al. Intracellular antibody receptor TRIM21 prevents fatal viral infection. Proc Natl Acad Sci U S A. 2013;110:12397–401.CrossRefPubMedPubMedCentral

23.

Higgs R, Ní Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol. 2008;181:1780–6.CrossRefPubMedPubMedCentral

24.

McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013;14:327–36.CrossRefPubMedPubMedCentral

25.

Lee OH, Lee J, Lee KH, Woo YM, Kang JH, Yoon HG, et al. Role of the focal adhesion protein TRIM15 in colon cancer development. Biochim Biophys Acta. 1853;2015:409–21.

26.

Chen N, Balasenthil S, Reuther J, Killary AM. DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity. Cancer Res. 2014;74:5683–9.CrossRefPubMedPubMedCentral

27.

Quintás-Cardama A, Post SM, Solis LM, Xiong S, Yang P, Chen N, et al. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol. 2014;234:108–19.CrossRefPubMedPubMedCentral

28.

Jia D, Wei L, Guo W, Zha R, Bao M, Chen Z, et al. Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology. 2011;54:1227–36.CrossRefPubMed

29.

Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, Mark M, et al. Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2011;108:8212–7.CrossRefPubMedPubMedCentral

30.

Jauharoh SN, Saegusa J, Sugimoto T, Ardianto B, Kasagi S, Sugiyama D, et al. SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production. Biochem Biophys Res Commun. 2012;417:582–7.CrossRefPubMed

31.

Zhang J, Fang L, Zhu X, Qiao Y, Yu M, Wang L, et al. Ro52/SSA sensitizes cells to death receptor-induced apoptosis by down-regulating c-FLIP (L). Cell Biol Int. 2012;36:463–8.CrossRefPubMed

32.

He P, Tang ZY, Ye SL, Liu BB, Liu YK. The targeted expression of interleukin-2 in human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2000;19:183–7.PubMed

33.

Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, et al. Ultra-low dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol. 2002;25:224–6.CrossRefPubMed

34.

Ikeguchi M, Hirooka Y. Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie. 2005;28:255–9.PubMed

35.

Ishii T, Ohnuma K, Murakami A, Takasawa N, Yamochi T, Iwata S, et al. SS-A/Ro52, an autoantigen involved in CD28-mediated IL-2 production. J Immunol. 2003;170:3653–61.CrossRefPubMed

36.

Wada K, Niida M, Tanaka M, Kamitani T. Ro52-mediated monoubiquitination of IKKβ down-regulates NF-kB signalling. J Biochem. 2009;146:821–32.CrossRefPubMedPubMedCentral

37.

Erstad DJ, Cusack Jr JC. Targeting the NF-κB pathway in cancer therapy. Surg Oncol Clin N Am. 2013;22:705–46.CrossRefPubMed

38.

Zheng T, Hong X, Wang J, Pei T, Liang Y, Yin D, et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology. 2014;59:935–46.CrossRefPubMed

39.

Kim YC, Cao Y, Pitterle DM, O’Briant KC, Bepler G. SSA/RO52gene and expressed sequence tags in an 85 kb region of chromosome segment 11p15.5. Int J Cancer. 2000;87:61–7.CrossRefPubMed

Title: Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers
Authors: Qianshan Ding
Du He
Ke He
Qian Zhang
Meng Tang
Jinfen Dai
Hanlin Lv
Xiaochen Wang
Guoan Xiang
Honggang Yu
Publication date: 01-11-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 11/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3572-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2015

Targeting increased copper levels in diethylnitrosamine induced hepatocellular carcinoma cells in rats by epigallocatechin-3-gallate

Modulation of PKC signaling and induction of apoptosis through suppression of reactive oxygen species and tumor necrosis factor receptor 1 (TNFR1): key role of quercetin in cancer prevention

Specific combinations of the chromatin-modifying enzyme modulators significantly attenuate glioblastoma cell proliferation and viability while exerting minimal effect on normal adult stem cells growth

Overexpression of Wnt7α protein predicts poor survival in patients with colorectal carcinoma

Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?

miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2

Keynote webinar | Spotlight on antibody–drug conjugates in cancer